Latest Study Reinforces Cosmetic Talc, Mesothelioma Link

Evidence continues to mount that prolonged exposure to cosmetic talcum powder contaminated by asbestos fibers is causing mesothelioma cancer. Individuals using cosmetic talc regularly may be putting themselves at higher risk, according to doctors at Peninsula Pathology Associates in Newport News, Virginia. They recently completed the most extensive case study to date on the topic. Mesothelioma is an aggressive cancer caused primarily by the inhalation or ingestion of asbestos fibers. Peninsula’s study involved 75 mesothelioma patients — including 64 women — who believed their only exposure to asbestos was through cosmetic talcum powder. The American Journal of Industrial Medicine published the study in March, just five months after a similar study at the Zucker School of Medicine at Hofstra/Northwell in New York detailed 33 other cases. “The findings of the present, and other recent studies, suggest that cosmetic talc may be a cause of malignant mesothelioma,” the latest co-authors wrote. “The present study supports the contention.” Mesothelioma Is More Than an Occupational Disease The evidence may help explain the growing number of mesothelioma patients — mostly women — who do not fit the stereotype of blue-collar workers exposed occupationally to asbestos. “Cosmetic talc may account for a percentage of the malignant mesotheliomas previously reported as ‘idiopathic,’ especially in women,” lead auth...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Conclusions: Our data show that TGFα but not its receptor EGFR is a key factor in resistance to MPM chemotherapy. This observation may contribute to casting light on the promising but still controversial role of EGFR signaling in MPM therapy.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
This study aims to evaluate micronuclei (MN) frequency as a biomarker of genome instability in peripheral blood lymphocytes of PM and lung cancer (LC) patients when compared with healthy controls (HCs) and patients with nonneoplastic respiratory diseases (RDs). Lymphocyte cytokinesis-block MN assay was carried out on 317 subjects. Mutagen sensitivity, measured by quantifying MN frequency after an in vitro challenge with ionizing radiation, was evaluated in 252 subjects. A significant increase in MN frequency was observed in cancer patients compared to HCs, with a mean ratio (MR) of 1.35 and 1.36 at baseline and 1.43 and 1....
Source: Journal of Environmental Pathology, Toxicology and Oncology - Category: Environmental Health Tags: J Environ Pathol Toxicol Oncol Source Type: research
British Journal of Cancer, Published online: 04 June 2020; doi:10.1038/s41416-020-0912-9Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionPeople with cancer residing outside major cities had lower survival from some cancers, which is partly due to the greater socio-economic disadvantage of rural residents.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
Malignant pleural mesothelioma (MPM) is a treatment recalcitrant tumor with a poor overall survival (OS). Current approved treatment consists of first line chemotherapy that only modestly increases OS, illustrating the desperate need for other treatment options in MPM. Unfortunately, clinical studies that investigate the effectivity of checkpoint inhibitor (CI) treatment failed to improve clinical outcome over current applied therapies. In general, MPM is characterized as an immunological cold tumor with low T-cell infiltration, which could explain the disappointing results of clinical trials investigating CI treatment in ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Doctors, scientists and occupational health experts from across the country are openly criticizing the U.S. Environmental Protection Agency’s recent asbestos draft risk evaluation. At a virtual press conference arranged by the Asbestos Disease Awareness Organization last week, speakers labeled the asbestos evaluation inadequate and in need of serious revision. The year-long evaluation was required as part of the Frank R. Lautenberg Chemical Safety for the 21st Century Act, which was passed in 2016. It amended the original Toxic Substances Control Act, the country’s primary chemicals management law. “I am...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
We examined 329 patients from February 2002 to July 2013. There were 131 MPM cases with ADA levels of 32.29 IU/L; 117 LC cases with ADA levels of 21.12 IU/L; 54 benign disease cases with ADA levels of 20.98 IU/L. A significant difference existed in pleural effusion ADA levels between MPM and benign disease patients. Pleural effusion ADA levels were significantly higher in MPM patients. PMID: 32468861 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
Abstract Iron is essential for all the lives on earth but may trigger a switch toward ferroptosis, a novel form of regulated necrosis. Carbonic anhydrases (CAs) are ubiquitous enzymes from microbes to humans. The primary function of CAs is to regulate cellular pH by hydrating carbon dioxide (CO2) to protons (H+) and bicarbonate ions (HCO3-). Furthermore, CAs play roles in biosynthetic reactions, such as gluconeogenesis, lipogenesis, ureagenesis and are also associated with tumor metabolism, suggesting that CAs may be a potential target for the treatment of cancers. We have recently revealed a novel function of CA ...
Source: Archives of Biochemistry and Biophysics - Category: Biochemistry Authors: Tags: Arch Biochem Biophys Source Type: research
Malignant pleural mesothelioma (MPM) is a highly aggressive cancer of the visceral or parietal pleura, with greater than 90% of cases occurring in the setting of asbestos exposure. It is a relatively rare cancer, with an incidence of approximately 10 per 1 million person-years in the United States. It has a long latency period, up to 20 years after asbestos exposure, and the median age of diagnosis is 75 years old. [1,2]
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
An international, much-anticipated phase III clinical trial that could change standard-of-care treatment for patients with malignant pleural mesothelioma will open soon, pending COVID-19 pandemic restrictions. The randomized trial will be studying the effectiveness of the immunotherapy drug durvalumab (Imfinzi) when used in combination with chemotherapy drugs pemetrexed (Alimta) and cisplatin for mesothelioma. Opening dates may vary by center because of the COVID-19 pandemic that has slowed or stalled clinical trials everywhere. Durvalumab produces an antibody that helps a patient’s own immune system kill tumor cell...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Babies | Cancer | Cancer & Oncology | Environmental Health | Food and Drug Administration (FDA) | Lawsuits | Legislation | Mesothelioma | Minerals | Occupational Health | Pathology | Science | Study | Women